anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
UNLABELLED: Many methods are being tried for rapid and accurate identification of sepsis-causing microorganisms. We analyzed the performance of three different preparation methods [MBT Sepsityper IVD Kit (Bruker Daltonics GmbH, Germany), sodium dodecyl sulfate (SDS) lysis, and differential centrifugation with protein extraction (Centrifugation +PE)] and compared in standard and Sepsityper modules of the Bruker Biotyper MALDI-TOF MS for direct identification of bacteria from 240 positive blood culture bottles of BACTEC FX (Becton Dickinson, USA). By using the standard module, correct identification at species level (score ≥2) was done in 46.7% of the samples with SDS lysis, 44.2% with centrifugation +PE, and 25.4% with the Sepsityper kit. These ratios at the genus level (score range 1.70-1.99) were 34.6%, 31.3%, and 32.5%, respectively. With SDS lysis (195), more bacteria were identified correctly than centrifugation +PE (181) and the Sepsityper kit (139). A statistically significant difference was found between SDS and the Sepsityper kit and Centrifugation +PE and the Sepsityper kit (P < 0.001, both). By using the Sepsityper module, correct identification at species level (score ≥1.8) was determined in 74.2% of the samples with SDS lysis and centrifugation +PE each and 55% with the Sepsityper kit. These ratios at the genus level (score range 1.60-1.79) were 16.3%, 10%, and 19.2%, respectively. SDS lysis (217) had significantly higher identification rates than centrifugation +PE (202) and the Sepsityper kit (178) (P = 0.028 and P < 0.001). A statistically significant difference was also observed between centrifugation +PE and the Sepsityper kit (P < 0.001). Best performance was obtained with SDS lysis among the methods. Although better performance was achieved by using Sepsityper software module, risk of misidentification should not be ignored.
IMPORTANCE: Sepsis is a life-threatening condition, and rapid and accurate identification of the causative microorganisms from blood cultures is crucial for timely and effective treatment. Although there are many studies on direct identification from blood cultures with MALDI-TOF MS, further standardization is still needed. In our study, we analyzed the performance of three different preparation methods and compared by using two analysis modules of the Bruker Biotyper MALDI-TOF MS for direct identification of bacteria from numerous positive blood culture bottles. The literature reports a limited number of studies that compare different preparation methods for direct blood culture identification, processing a large number of blood samples concurrently and evaluating the same samples as in our study. Moreover, although SDS is used very frequently in medical laboratories, there are few studies on direct identification from blood culture bottles. In our study, the highest correct identification rate was observed with the SDS method.
During Run-in Period, participants will be dosed with 300 mg of allopurinol from Day -7 to Day -1. During the Treatment Period, participants will be administered 24 mg verinurad with 300 mg allopurinol once daily on Days 1 to 7.
The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.
The invention discloses a Vibrio harveyi high-efficiency lytic bacteriophage vB _ Vhas-yong1 and application thereof, and relates to biological treatment of Vibrio harveyi pollution and infection. The vB _ Vhas-yong1 is preserved in the general microbiological center of the culture Collection of microorganisms with the preservation number of CGMCC No. 18193. The genome of vB _ Vhas-yong1 is double-stranded DNA with the total length of 82703bp, the sequence of the DNA does not exist in the existing database, and the DNA is a novel unreported phage. The vB VhaS-yong1 genome contains 126 ORFs and does not encode toxins and antibiotic resistance genes. vB _ Vhas-yong1 has obvious protective effect on animals. Use of vB _ Vhas-yong1 for specifically inhibiting and killing highly pathogenic Vibrio harveyi.
Calcitonin-Salmon Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females. Calcitonin-Salmon Nasal Spray should be reserved for patients who refuse or cannot tolerate estrogens or in whom estrogens are contraindicated. Use of Calcitonin-Salmon Nasal Spray is recommended in conjunction with an adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (400 I.U. per day) intake to retard the progressive loss of bone mass. The evidence of efficacy is based on increases in spinal bone mineral density observed in clinical trials.

Two randomized, placebo controlled trials were conducted in 325 postmenopausal females [227 Calcitonin-Salmon Nasal Spray treated and 98 placebo treated] with spinal, forearm or femoral bone mineral density (BMD) at least one standard deviation below normal for healthy premenopausal females. These studies conducted over two years demonstrated that 200 I.U. daily of Calcitonin-Salmon Nasal Spray increases lumbar vertebral BMD relative to baseline and relative to placebo in osteoporotic females who were greater than 5 years postmenopause. Calcitonin-Salmon Nasal Spray produced statistically significant increases in lumbar vertebral BMD compared to placebo as early as 6 months after initiation of therapy with persistence of this level for up to 2 years of observation.

No effects of Calcitonin-Salmon Nasal Spray on cortical bone of the forearm or hip were demonstrated. However, in one study, BMD of the hip showed a statistically significant increase compared with placebo in a region composed of predominantly trabecular bone after 1 year of treatment changing to a trend at 2 years that was no longer statistically significant.
PURPOSE:To enable the performing of a comparative observation by one display means by arranging an image display device to display a plurality of images of the same part of the same person to be inspected with an alternate switching thereof at a set time interval. CONSTITUTION:A control section 9 sets a switch SW to a position (a) terminal to read out an image A stored in an original image memory 3a and the image is let pass through an image processing section 4 and a postprocessing image memory 5a to be transferred to a memory 6 for display. An image data is read out sequentially to be converted into an analog video image with a D/A converter to be displayed on a monitor 8. Watching the monitor 8 a physician switches a display image over to an image B stored in an original image memory 3b at a proper time and the image B is displayed on the monitor 8. The physician views the two images A and B to specify a necessary image processing. For example, when the two images differ in size, expansion or reduction is directed to make the sizes thereof coincide with each other. When they deviate in position, a processing is directed for rotary or parallel movement. A control section 9 controls the image processing section 4 so as to execute a processing directed.
BACKGROUND: The appearance of striae gravidarum (SG) during pregnancy is a common problem. The most common SG are abdominal striae, which can cause the greatest sequelae after pregnancy, and in the long term. There are several solutions to prevent and treat these striae, but not all are completely effective, and not without side effects.
AIMS: The aim of this study was to evaluate the effectiveness of a treatment that applies an electromagnetic field under vacuum (V-EMF therapy) on the abdominal SG.
METHODS: A retrospective analysis was conducted on the medical records of 26 women affected by abdominal SG and treated with V-EMF therapy. The results were evaluated using two different 5-point Likert Scales: one administered to the treated subjects to evaluate their satisfaction, and one to the doctors who performed the treatment, to evaluate the improvement of the striae. The presence of side effects, and the effects of sun exposure after treatment were also considered.
RESULTS: Only two treated subjects rated their level of satisfaction with a Score III on the Liker Scale. Everyone else expressed higher levels of satisfaction. Only one doctor rated the improvement of the striae with a Liker scale score of III. All the others reported greater improvements. No discomfort or side effects were noted either during the individual treatment sessions, or at the end of the treatment. The striae showed a newfound ability to tan.
CONCLUSIONS: V-EMF therapy proves to be a valid, safe, and effective treatment modality for SG.
A system and method for scheduling healthcare-related services. The method includes receiving identifying data associated with a user. The method further includes presenting service(s) available to the user based on the data associated with the user. The method also includes receiving a selection of the service(s) presented to the user. The method further includes sending a service request message to one or more clinicians based on the received identifying data and the selection of the service(s). The method additionally includes receiving a confirmation message indicating a physician's confirmation to provide the service(s). The method also includes scheduling a time and location for the clinician to provide the service(s).
<P>PROBLEM TO BE SOLVED: To obtain a medicine for promoting ceramide transportation and a base sequence for producing the medicine and to provide a method for assaying activity for promoting ceramide isolation and a method for assaying activity for promoting ceramide intermembrane movement.  <P>SOLUTION: The medicine for promoting ceramide transportation comprises protein having an amino acid sequence of sequence number 1 as an active ingredient. The base sequence of sequence number 5 is used for producing the medicine. The method for assaying activity for promoting ceramide isolation comprises mixing a ceramide-containing lipid membrane with a medicine for promoting ceramide isolation to give a mixture, separating the mixture by centrifugation to give a supernatant and determining ceramide contained in the supernatant. The method for assaying activity for promoting ceramide intermembrane movement comprises mixing a receiving membrane with the medicine for promoting ceramide transportation and a ceramide-containing donating membrane to give a mixture, adding a selective membrane flocculant to the mixture, separating the receiving membrane from the donating membrane by centrifugation and determining ceramide contained in the separated receiving membrane and donating membrane.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND: Hypertension may result in atrial fibrillation (AF) and lipid metabolism disorders. The Sirtuins3 (SIRT3)/AMP-activated protein kinase (AMPK) signaling pathway has the capacity to regulate lipid metabolism disorders and the onset of AF. We hypothesize that the SIRT3/AMPK signaling pathway suppresses lipid metabolism disorders, thereby mitigating salt-sensitive hypertension (SSHT)-induced susceptibility to AF.
METHODS: The study involved 7-week-old male Dahl salt-sensitive that were fed either a high-salt diet (8% NaCl; DSH group) or a normal diet (0.3% NaCl; DSN group). Then DSH group was administered either oral metformin (MET, an AMPK agonist) or intraperitoneal injection of Honokiol (HK, a SIRT3 agonist). This experimental model allowed for the measurement of Systolic blood pressure (SBP), the expression levels of lipid metabolism-related biomarkers, pathological examination of atrial fibrosis, and lipid accumulation, as well as AF inducibility and AF duration.
RESULTS: DSH decrease SIRT3, phosphorylation-AMPK, and very long-chain acyl-CoA dehydrogenase, (VLCAD) expression, increased FASN and FABP4 expression and concentrations of free fatty acid and triglyceride, atrial fibrosis and lipid accumulation in atrial tissue, enhanced level of SBP, promoted AF induction rate and prolonged AF duration, which are blocked by MET and HK. Our results also showed that the degree of atrial fibrosis was negatively correlated with VLCAD expression, but positively correlated with the expression of FASN and FABP4.
CONCLUSIONS: We have confirmed that a high-salt diet can result in hypertension, and associated atrial tissue lipid metabolism dysfunction. This condition is linked to the inhibition of the SIRT3/AMPK signaling pathway, which plays a significant role in the progression of susceptibility to AF in SSHT rats.
Late differentiation antigens (LDA1 and LDA2) expressed by activated helper cells are described. LDA1 and LDA2 are membrane proteins recognized by monoclonal antibodies produced by immunizing mice with alloreactive human T cell clones with helper function. LDA1 and LDA2 are expressed by helper T cells. LDA1 monoclonal antibody and LDA2 monoclonal antibody block T cell enhancement of B cell immunoglobulin production. Thus, LDA1 and LDA2 are associated with helper T cell effector function. Methods of diagnosis and therepy based upon LDA1 and LDA2 are also described.
Aspirin is widely used for both primary and secondary prevention of panvascular diseases, such as stroke and coronary heart disease (CHD). The optimal balance between reducing panvascular disease events and the potential increase in bleeding risk remains unclear. This study aimed to develop a predictive model specifically designed to assess bleeding risk in individuals using aspirin. A total of 58,415 individuals treated with aspirin were included in this study. Detailed data regarding patient demographics, clinical characteristics, comorbidities, medical history, and laboratory test results were collected from the Affiliated Dongyang Hospital of Wenzhou Medical University. The patients were randomly divided into two groups at a ratio of 7:3. The larger group was used for model development, while the smaller group was used for internal validation. To develop the prediction model, we employed least absolute shrinkage and selection operator (LASSO) regression followed by multivariate logistic regression. The performance of the model was assessed through metrics such as the area under the receiver operating characteristic (ROC) curve (AUC), calibration curves, and decision curve analysis (DCA). The LASSO-derived model employed in this study incorporated six variables, namely, sex, operation, previous bleeding, hemoglobin, platelet count, and cerebral infarction. It demonstrated excellent performance at predicting bleeding risk among aspirin users, with a high AUC of 0.866 (95% CI 0.857-0.874) in the training dataset and 0.861 (95% CI 0.848-0.875) in the test dataset. At a cutoff value of 0.047, the model achieved moderate sensitivity (83.0%) and specificity (73.9%). The calibration curve analysis revealed that the nomogram closely approximated the ideal curve, indicating good calibration. The DCA curve demonstrated a favorable clinical net benefit associated with the nomogram model. Our developed LASSO-derived predictive model has potential as an alternative tool for predicting bleeding in clinical settings.
Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
The present invention relates to use of a sugar or a sugar alcohol eg. glycerol for protection of skin against harmful bacteria. The present invention is especially useful in formulating compositions which act as prebiotics by skin commensal bacteria like  S .  epidermidis  to produce metabolites like lactic acid which by way of the present invention has been shown to inhibit growth of harmful bacteria like  E. Coli  and  S . Aureus. The present invention is advantageous in that there is no need to use conventional antimicrobial actives which may destroy the skin microbiome.
Duodenal adenocarcinoma is a rare digestive cancer, often diagnosed at a late stage and harbours a poor prognosis. The arrival of immunotherapy has changed the prognosis of many neoplasia, including digestive adenocarcinomas with MSI-H status. Hereby, we describe three cases of MSI-H locally advanced duodenal adenocarcinoma who received neoadjuvant treatment with a PD1 inhibitor, pembrolizumab. A partial metabolic and endoscopic response was observed in all patients after 2 cycles. Duodenopancreatectomy was performed at the end of treatment (4-6 cycles), and anatomopathological analysis demonstrated pathological complete response in all patients. Our case series paves the way for prospectively exploring neoadjuvant immunotherapy in duodenal MSI-H adenocarcinoma and raises the question of organ sparing surgery in case of complete clinical response as observed in gastric and colo-rectal adenocarcinomas.
This is an early phase study to evaluate the safety and efficacy of the combination of tadalafil with lenalidomide and dexamethasone (Rd) or BiRd. 19 patients on Rd or BiRd will be treated with tadalafil for a minimum of 6 months. The investigational drug will be discontinued if there is evidence of disease progression as defined by the International Uniform Response criteria \[1\]. For responding patients (patients who have a CR, VGPR, PR or SD), the therapy will be continued until progression or intolerable adverse effects. Blood and bone marrow will be collected for various studies as detailed in section 14.10. Clinical response will be monitored every month during the study.
The study will be conducted at the departments of Obstetrics and Gynecology of Sohag, Qena, Al Azhar, and Assuit university hospitals, Egypt. All patients with atonic PPH who delivered vaginally will be invited to participate in the study. Patients who delivered by caesarean section, with retained placenta, with traumatic PPH, associated coagulopathy and those refused to participate in the study will be excluded. The patients will be randomly categorized into 3 groups; the first (n = 100) will receive 30 IU oxytocin intravenously; the second (n = 100) will receive 600 ug misopristol sublingually; the third (n = 100) will receive 100 ug Carbetocin IV. The randomization will be done using opaque sealed envelops containing computer-generated codes. The primary outcome of the study is cessation of bleeding which will be judged by visual inspection of the blood loss by the trialist and by loss of \< 300 mL of blood during the first hour after enrollment. The secondary outcomes are time of control of bleeding (minutes), amount of blood loss till control of bleeding (mL), changes in the hemoglobin levels (gm) before and after treatment, Changes in the hematocrite values (%) before and after treatment, the use of additional uterotonic drugs, the rate of complications (%), and the necessity for surgical intervention, and the cost of each medication.

Written consent will be obtained from all participants and approval from the local institutional ethical committee will be included.
PURPOSE:To provide the titled composition containing polystyrene-sulfonic acid or its salt as a substrate, usable as a hair-care product or skin-care product without giving adverse affect to the main active component of a cosmetic composition and giving excellent feeling in application and finishing. CONSTITUTION:A polystyrenesulfonic acid or its salt is used as a substrate. The molecular weight of the polystyrenesulfonic acid is preferably 3,000-1,000,000, especially 5,000-50,000. The counter ion of the salt is preferably sodium, potassium, ammonium, etc. The amount of the compound in the composition is preferably 0.1-5wt.% for hair-care product such as shampoo or rinse and about 0.5-10wt.% for skin-care product. The polystyrenesulfonic acid can be produced e.g. by sulfonating polystyrene with a sulfonation agent such as sulfuric acid and separating unreacted polystyrene by filtration.
NEW MATERIAL:The compound of formula I (R is group of formula II, formula III, etc.) and its hydrochloride. EXAMPLE:Pentanedioic acid mono[{2-(1-methylethyl)amino}-1-{(1-naphthaleneoxy) methyl}ethyl] ester hydrochloride. USE:A compound effective in improving the bioavailability of propranolol useful as a beta-blocker. It is absorbed through digestive tracts by oral administration, transferred to blood without being affected by 1st passage through the liver and converted into propranolol. PREPARATION:The compound of formula I can be produced either by bonding propranolol with glutaric anhydride or maleic anhydride through ester bond or by bonding propranolol with glutaric anhydride through ester bond and reacting the product with a methyl halide or ethyl halide.
BACKGROUND AND AIMS: According to previous studies, triglyceride-glucose (TyG) is related to chronic kidney disease (CKD), but no studies have explored the correlation between TyG and CKD among adults with metabolic dysfunction-associated fatty liver disease (MAFLD). We aimed to explore the associations of the TyG index with CKD among adults with MAFLD.
METHODS: In this retrospective observational cohort study, data from 11,860 participants who underwent a minimum of three health assessments between 2008 and 2015 were retrospectively collected. Participants were followed up until the final medical visit or health examination. CKD refers to an eGFR < 60 mL/min per 1·73 m2 or the occurrence of two or more incidents of proteinuria.
RESULTS: Within a median 10·02-year follow-up period, 2005 (16·9%) participants reported developing CKD. Multivariate Cox regression models indicated a noticeable correlation between the TyG index and CKD incidence (HR per unit increase, 1.19; 95% CI: 1.09-1.29) and between the TyG index and CKD incidence (HR per SD increase, 1.12; 95% CI: 1.06-1.18). The CKD incidence increased by 1.8 times in participants in the highest TyG index quartile relative to patients in the lowest quartile of the TyG index quartile (HR 1·18, 95% CI: 1.01-1.38, P = 0.007). According to subgroup analysis, an elevated TyG index is likely to become more harmful to participants younger than 60 years (P for interaction = 0.035).
CONCLUSION: An elevated TyG index may increase CKD incidence among MAFLD adults, particularly among younger people. Early intervention may help reduce the incidence of CKD.
A cosmetic composition that allows for the suspension of beads of differing sizes is disclosed. This cosmetic composition will allow the beads to remain suspended but is not too viscous to destroy or significantly reduce the desired qualities in the cosmetic composition, e.g., body gel. This includes the primary ingredients of a carbomer solution (with a neutralizing agent) and a gum solution. Optional ingredients can include, but are not limited to, a surfactant, a chemical to lower the freezing point, a preservative, a fragrance, and hair and skin treatment additives. The beads are preferably formed from a wide variety of shell materials that house a core oil. The aesthetic qualities of this cosmetic composition are very pleasing in addition to the performance provided by the suspended beads.
Patients receive paclitaxel IV on days 1, 8, and 15 and ipatasertib PO on days 1-21. Treatment repeats every 28 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and follow-up.